linjc16/ctgov huggingface dataset:
Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL

Study Overview
=================
Brief Summary
-----------------
Retrospective collection of data from medical records, multicenter, post-market clinical follow-up study.

Official Title
-----------------
Evaluation of Real-World Data on the Performance of the TECNIS Odyssey™ IOL

Conditions
-----------------
Cataracts

Intervention / Treatment
-----------------
* Device: Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Previously bilaterally implanted with TECNIS Odyssey IOL, following cataract extraction; Enrollment at least 21 days after second eye surgery; Clear intraocular media in each eye. Signed consent and data protection documentation necessary to comply with applicable privacy laws pertaining to medical treatment in the governing countries. Exclusion Criteria: Concurrent participation in an interventional clinical trial during the time from which the data will be collected; Use of systemic or ocular medication that may affect vision; Prior corneal refractive surgery in each eye (i.e., LASIK, PRK, SMILE, RK, CK); NOTE: Limbal relaxing incisions (LRI) are permissible as planned at the time of surgery (intraoperatively) but not postoperatively within the retrospective analysis window; Ongoing adverse events in each eye that might impact outcomes during the study visit as determined by the investigator; Acute or chronic disease or condition, ocular trauma or surgery that may affect vision in each eye (e.g., clinically significant macular degeneration, glaucoma, cystoid macular edema, proliferative diabetic retinopathy, keratoconus etc.). Amblyopia, strabismus, nystagmus in each eye.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Intervention|No study treatments will be administered during this retrospective study. However, data will be collected from medical records of patients who have been treated with the subject device of this study.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity | Visual Acuity will be collected via observed case data in units of logMAR. | 1-month postoperative | 
| Manifest Refraction | Manifest Refraction will be collected via observed case data in units of diopters. | 1-month postoperative | 
| Visual Symptoms/Complaints | Visual Symptoms/Complaints will be measured using a questionnaire on a 5-point scale. | 1-month postoperative |
Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars

Study Overview
=================
Brief Summary
-----------------
Recently, few studies have attempted to test the regenerative effects of human insulin application by microneedling on atrophic scars versus other topical preparations. However, the scars were limited etiologically to acne scars. In addition, a lack of inclusion of a control group instead of comparing topical preparations with insulin was also a limitation to these studies. A control group consisting of microneedling alone would have served as a better comparison in order to determine whether the effects of microneedling are augmented by topical protein-rich preparations.

Official Title
-----------------
Microneedling With Regular Insulin Versus Microneedling Alone in Treatment of Atrophic Scars

Conditions
-----------------
Scars, Insulin

Intervention / Treatment
-----------------
* Other: Microneedling with topical application of regular insulin
* Other: Microneedling with topical application of saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged 12 to 60 years Atrophic scars (traumatic or surgical) Completely healed scars Exclusion Criteria: Patients with a tendency or history of hypertrophic or keloidal scars Patients who received treatment for their scar in the past 3 months Diabetic patients or those with a history of Dysglycemia Pregnant, or lactating females Patients with active infection at the site of scar Patients currently receiving isotretinoin treatment or in the past month

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Microneedling with topical application of regular insulin<br> | Other: Microneedling with topical application of regular insulin<br>* Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group<br>|
| Active Comparator: Microneedling only<br> | Other: Microneedling with topical application of saline<br>* Microneeling preformed onto the scar In one group insulin will be applied while saline will be used in the second group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Scar | According the different scar assessment scores (e.g.POSAS score - The Patient and Observer Scar Assessment Scale score, range from 6 to 60, the higher the score the worse the scar, lowering in the score denotes improvement ) | 4 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Insulin, scars
Screening and Secondary Prevention Rheumatic Heart Disease Study

Study Overview
=================
Brief Summary
-----------------
After basic clinical screening including history and physical, Point of care ultrasound will be performed to look at Mitral, Aortic and Tricuspid Valves for regurgitation or stenosis. For patients with confirmed Rheumatic heart disease (RHD), treatment and referral depending on stage of disease. Antibiotic prescription could be shifted to community health workers delivering preventive medications via practical clinical algorithms, diagnostic tools, availability of appropriate antibiotics, and supportive supervision. Patients will have repeat imaging at 2 years and 5 years to look at the outcome of delayed progression of valve disease.

Detailed Description
-----------------
Screening for RHD should be carried out since it is a major health concern that has been shown to have a treatable and detectable latent stage that can be diagnosed using a simple sensitive test (point of care ultrasound) and early treatment (secondary prevention using antibiotic prophylaxis) can provide a better outcome (slow progression of disease) in a cost effective way. The investigators aim to study the Incidence and Prevalence of RHD in community and school settings and aim to intervene depending on the stage the disease is picked up in.

Official Title
-----------------
Screening and Secondary Prevention Rheumatic Heart Disease

Conditions
-----------------
Rheumatic Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Rural communities in Sindh Exclusion Criteria: Refused to participate in the study

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rheumatic heart disease | Number of patients | At the time of screening echocardiogram |
Management of OAB in Female Patients .

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to compare the effectiveness of mirabegron, solifenacin, tadalafil (5mg), and their combination in relieving symptoms of overactive bladder (OAB) in a double-blinded prospective randomized placebo-controlled trial.

Official Title
-----------------
Assessment of Efficacy of Mirabegron, Solifenacin, Tadalafil 5mg and Combination Therapy in Female Patients With Overactive Bladder: A Double Blinded Prospective Randomized Placebo -Controlled Trial

Conditions
-----------------
Overactive Bladder

Intervention / Treatment
-----------------
* Drug: Solfenacin
* Drug: Mirabegron
* Drug: Tadalafil 5mg


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women from 18 to 65 years of age with LUTs due to OAB Exclusion Criteria: Severe cardiovascular disorders. \ Severe neurogenic dysfunction. Drug administration which interfere with bladder function . Abnormal bleeding profile. A verified urinary tract infection as determined by urinalysis and/or urine culture during screening

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Group A : patients will receive mirabegron<br>patients will receive mirabegron | Drug: Mirabegron<br>* pills taken once day<br>|
| Active Comparator: Group B: patients will receive tadalafil 5mg<br>patients will receive tadalafil 5mg | Drug: Tadalafil 5mg<br>* pills taken once day<br>|
| Active Comparator: Group C: patients will receive solfenacin<br>patients will receive solfenacin | Drug: Solfenacin<br>* pills taken once day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| overactive bladder symptoms. | evaluated for overactive bladder symptoms | three months |
Evaluation of Hand Grip Strength in Pregnant COVID-19 Patients

Study Overview
=================
Brief Summary
-----------------
It was presented as a cross-sectional, single-center, retrospective case series. Pregnant women with a positive Polymerase Chain Reaction (PCR) diagnosis of Covid 19 were included in the study. The relationship between patients' musculoskeletal symptoms and signs and hand grip strength was investigated.

Detailed Description
-----------------
Covid 19 is the disease defined for strains infected with severe acute respiratory syndrome coronavirus 2(Sars-CoV-2). Hand grip strength is a non-invasive, easily applicable, objective parameter. It was presented as a cross-sectional, single-center, retrospective case series. Pregnant women with a positive Polymerase Chain Reaction (PCR) diagnosis of Covid 19 were included in the study. The relationship between patients' musculoskeletal symptoms and signs and hand grip strength was investigated.

Official Title
-----------------
Musculoskeletal Pain in Pregnant Infected With COVID-19, Evaluation of Fatigue and Muscle Grip Strength

Conditions
-----------------
COVID-19, Pregnancy Related

Intervention / Treatment
-----------------
* Device: Hand grip strength measureme


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women with a positive Polymerase Chain Reaction (PCR) diagnosis of Covid 19 Exclusion Criteria: Those with orthopedic defects in the dominant hand and wrist and those with hand, wrist and shoulder involvement on the side of the measurement related to rheumatological diseases were excluded from the study.
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| pregnant covid 19 patients<br>pregnant covid 19 patients | Device: Hand grip strength measureme<br>* Hand grip strength (HSG) was measured in kg with the CAMRY Digital Hand Dynamometer (Model No. EH101, CAMRY).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hand grip strength assessment | Hand grip strength assessment in pregnancy Covid 19. | The first 24 hours after admission to the service. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| symptoms | Common symptoms of pregnant Covid 19 patients. | The first 24 hours after admission to the service. | 
| laboratory findings | Common laboratory findings of pregnant Covid 19 patients. | The first 24 hours after admission to the service. | 
| Vaccine | Vaccine rate of pregnant Covid 19 patients. | pre-infection period was questioned | 
| Smoking | Smoking rate of pregnant Covid 19 patients. | pre-infection period was questioned | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COVID-19, Musculoskeletal Symptom, Hand Grip Muscle Streng
Electrophysiological Signatures of Distinct Working Memory Subprocesses That Predict Long-term Memory Success

Study Overview
=================
Brief Summary
-----------------
Healthy young adults will view pictures of items while the investigators record electroencephalogram (EEG) brain activity. Then, the investigators will ask the participants to report which items the participants remember seeing. The investigators will examine how the measured brain activity relates to which pictures the participants remember.

Detailed Description
-----------------
Electrophysiological signatures track distinct subprocesses of working memory, including the number of items and the spatial locations of those items. By identifying how these subprocesses predict long-term memory success in healthy young adults, this project should lead to an intricate understanding of the relationship between working memory and long-term memory. This study will investigate when and how long-term memory failures arise, by using sophisticated machine learning analyses of neural data. Moreover, this study will test the extent to which the investigators can track working memory processes in real time and how the investigators can leverage that information to improve long-term memory success. This will inform basic theories of the relationship between working memory and long-term memory and motivate future applications.

Official Title
-----------------
Electrophysiological Signatures of Distinct Working Memory Subprocesses That Predict Long-term Memory Success

Conditions
-----------------
Memory, EEG

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: normal or corrected to normal vision Exclusion Criteria: non-fluent in English

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: No intervention|There is no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Memory performance | To measure recognition memory performance, participants will view pictures and respond as to whether they remember previously seeing these items. Participants will be shown both old and new items. In the long-term memory phase, they will report their confidence at having seen each image using a four point rating scale, ranging from being confident the item is new (i.e., not previously seen) to being confident the item is old (i.e., previously seen). | This task is performed multiple time within the experimental session, which in total lasts around 3 hours. |
A Retrospective Cohort Study for Main Postoperative Complications After SARS-CoV-2 Infection

Study Overview
=================
Brief Summary
-----------------
To explore the relationship between SARS-CoV-2 infection in different time before operation and postoperative main complications (mortality, main pulmonary and cardiovascular complications) 30 days after operation; To determine the best timing of surgery after SARS-CoV-2 infection.

Official Title
-----------------
Main Postoperative Complications After SARS-CoV-2 Infection: A Retrospective Cohort Study

Conditions
-----------------
Intestines Cancer, Pulmonary Cancer, Liver Cancer, Trauma, Fractures, Bone, Gynecologic Disease

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age≥18 years; Patients undergoing any type of surgery in operating room. Exclusion Criteria: Surgery under local anesthesia (without participation of anesthetist) Surgery outside the operating room, such as gastrointestinal endoscopy, puncture biopsy, etc Patients who cannot determine whether they have had SARS CoV-2 infection before surgery.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All-cause mortality at 30 days after operation | All-cause mortality at 30 days after operation | 30 days after surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Main pulmonary complications at 30 days after operation | a composite of postoperative pneumonia, acute respiratory distress syndrome (ARDS) and unexpected ventilation | 30 days after surgery | 
| Major Adverse Cardiovascular Events (MACE) | a composite of cardiogenic death, myocardial infarction, new-onset heart failure or cardiogenic shock, and cerebrovascular accident (CVA) | 30 days after surgery |
Influencing Factors of the Diagnostic Accuracy of Novel Coronary Functional Evaluation Methods

Study Overview
=================
Brief Summary
-----------------
In this study, patients were retrospectively included, univariate and multivariate analysis of factors affecting their diagnosis inconsistencies was performed, and a new diagnostic model was constructed by logistic regression.

Detailed Description
-----------------
The evaluation of coronary function is becoming more and more important in the guidelines, in which coronary flow reserve (FFR) is the gold standard for diagnosis, but its measurement process requires the application of adenosine, vasodilator, etc. Some patients cannot be measured because of asthma and low blood pressure. A new instantaneous wave-free ratio (iFR), contrastive flow reserve fraction (cFFR) and quantitative flow fraction (QFR) have been developed for the evaluation of coronary function. However, in some patients, the new coronary function evaluation methods were inconsistent with FFR. In this study, patients were retrospectively included, univariate and multivariate analysis of factors affecting their diagnosis inconsistencies was performed, and a new diagnostic model was constructed by logistic regression.

Official Title
-----------------
Influencing Factors of the Diagnostic Accuracy of Novel Coronary Functional Evaluation Methods: a Cross-sectional Study

Conditions
-----------------
Coronary Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age above 18 and below 80 years old, regardless of gender; FFR was detected by coronary angiography; The coronary angiography images were clear, meeting the requirements of QFR analysis or detecting iFR, cFFR, and resting pd/pa during the operation. Exclusion Criteria: 1) Coronary artery bypass graft (CABG); 2) Atrial fibrillation or flutter; 3) Left or right coronary opening lesions; 4) Pregnancy or breastfeeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| FFR<br>In this single-center cross-sectional study, we included patients with non-acute myocardial infarction who were admitted to the Department of Cardiology at Peking University Third Hospital for FFR testing from January 2019 to December 2021. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the discordance between fractional flow reserve and quantitative flow ratio | If FFR≤0.80 and QFR ≤0.8 or FFR > 0.80 and QFR > 0.8 are consistent groups, otherwise they are inconsistent group | When the patient has completed coronary angiography and received a diagnosis |
Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Neoadjuvant immunotherapy has become the standard perioperative treatment in lung cancer, but its effective predictive biomarkers are lacking. A small cohort reported that homologous recombination deficiency (HRD) can be used as a reliable biomarker to predict the efficacy of neoadjuvant immunotherapy, but the findings need to be validated in larger cohorts. Moreover, circulating tumor DNA (ctDNA) has the potential to predict the therapeutic efficacy of neoadjuvant immunotherapy. This study intends to prospectively collect patients with driver-negative stage II-IIIB NSCLC who are scheduled to receive neoadjuvant immunotherapy and surgical resection and verify the value of HRD in predicting the efficacy of neoadjuvant immunotherapy. Meanwhile, the blood samples before and after neoadjuvant immunotherapy were collected for high-depth ctDNA detection to explore the correlation between the dynamic changes of ctDNA and the efficacy and prognosis of neoadjuvant immunotherapy.

Official Title
-----------------
A Biomarker Study for Predicting the Response of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer Based on Circulating Tumor DNA and Homologous Recombination Deficiency Analysis

Conditions
-----------------
Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stage II-IIIB NSCLC EGFR/ALK negative The subjects voluntarily joined the study, signed informed consent, had good compliance, and cooperated with follow-up Exclusion Criteria: A history of other malignancies within the past 5 years Patients with autoimmune disease are not suitable for PD1 monoclonal antibody therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between HRD and MPR rate/2 years DFS | Correlation between homologous recombination deficiency (HRD) events and major pathological response (MPR) rate and DFS of 2 years | 2023/12-2025/12 |